UI-014 is under clinical development by Korea United Pharm and currently in Phase I for Endocrine Gland Disorders. According to GlobalData, Phase I drugs for Endocrine Gland Disorders have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UI-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

UI-014 overview

UI-014 is under development for the treatment of endocrine, unspecified nutritional, metabolic diseases and hyperlipidaemia. It is administered through oral route. The drug candidate is an incrementally modified drug.

Korea United Pharm overview

Korea United Pharm (KUP) is a pharmaceutical company that produces, markets, sells and distributes pharmaceutical and other healthcare products. It offers incrementally modified drug, anti-cancer, prescription, OTC products, and others. The company provides anti-cancer products such as bleomycin sulfate, carboplatin, cyclophosphamide, dactinomycin and daunorubicin HCl, among others. KUP provides API products such as talniflumate, simvastatin, paroxetine and carvedilol. The company offers prescription product such as iohexol, arginine thiazolidine carboxylate, domperidone maleate, adefovir dipivoxil, entecavir, trimebutine maleate, and omeprazole enteric granule, among others. Its products are used in the therapeutic areas of gastrointestinal, cardiovascular, hematopoietic, respiratory, central nervous system, musculoskeletal, endocrine and metabolic, and other disorders. The company operates through its branch offices located in the Philippines, Vietnam, Myanmar, China, and others. KUP is headquartered in Seoul, South Korea.

For a complete picture of UI-014’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.